Back in July we previewed the FDA advisory committee meeting where seven popular research peptides were up for a decision, and outlined the political battle between the agency’s career scientists and a committee reshaped under Health Secretary Robert F. Kennedy Jr. The meeting happened on 23-24 July. The vote went the way the community hoped, against the agency’s own staff, but with a lot of caveats attached.
Here is what actually happened, what it means, and the parts nobody should over-read.
The vote
The Pharmacy Compounding Advisory Committee voted over the two-day hearing to recommend that six peptides be added to the FDA’s 503A Bulks List:
- BPC-157
- TB-500 (thymosin beta-4)
- MOTS-c
- KPV
- Epitalon
- Semax
A seventh compound, emideltide, was rejected on the grounds of particularly weak evidence - its clinical studies used an intravenous route while it was proposed as a subcutaneous injection, and the supporting data was a single patient case report for narcolepsy plus two small uncontrolled studies for opioid withdrawal.
The vote was not unanimous and it was not clean. It was a narrow win that exposed a deep split inside the institutions that regulate these compounds.
The split
The headline conflict is between the committee and FDA staff. Agency scientists had unanimously opposed adding every peptide on the list, citing the lack of solid clinical trial data, inconsistent recipes from batch to batch, and the risk of harmful immune reactions. That is the professional judgment of the people whose job is to assess exactly this.
On the other side, six of the eight recently appointed committee members run clinics that offer peptides. They framed their yes votes as harm reduction: if the choice is between a regulated compounding pathway and a booming online black market where people buy unregulated “research chemicals” with no doctor involved and no guarantee of what is in the vial, they argued the regulated pathway is the safer option.
Committee member Dr Haleem Mohammed said it directly: “As a physician, I have to make sure that I’m keeping patients as safe as possible. So, when I look at something like saying no to this and pushing it to the gray market, am I doing greater harm? That’s what I lose sleep at night over.”
The counter-argument came just as directly from Georgetown professor Dr Adriane Fugh-Berman during public testimony: “Would the government endorse manufacturing heroin because it’s cleaner than what is sold on the street? Just because a market is large doesn’t mean that a product should be legalized. It means that a product should be studied.”
That is the whole debate in two sentences, and it is essentially the same debate playing out in Australia, at the TGA, and in every other jurisdiction watching the peptide boom.
What the vote actually does
The most important thing to understand: the vote is advisory and non-binding. It still needs sign-off from the FDA itself, and there is no statutory deadline forcing a decision. Kennedy, who oversees the FDA via HHS, has publicly supported expanded peptide access, which is why the committee was reconstituted in the first place - but a committee recommendation is not an approval.
If the FDA does ultimately accept the recommendation, being on the 503A Bulks List creates a legal pathway for compounding pharmacies to manufacture these peptides under physician supervision, with purity testing and labelling standards. It does not make them FDA-approved drugs. It does not make them supplements you can grab off a shelf. It does not mean the FDA has declared them safe or effective.
For anyone currently sourcing these compounds from less regulated channels, that difference is the whole point: a compounding pathway, however imperfect, brings product into a system with batch records, testing and accountability.
What the Research Says
Evidence on the compounds themselves, honestly summarised:
- BPC-157 has a substantial body of preclinical research on tissue protection and healing, but no large randomised controlled trials in humans.
- TB-500 (thymosin beta-4) has been studied for wound healing and tissue repair, again mostly preclinically.
- MOTS-c is a mitochondrial-derived peptide with metabolic research interest and limited human data.
- KPV, Epitalon and Semax have thinner but real research histories - KPV as an anti-inflammatory peptide fragment, Epitalon in ageing research, Semax as a synthetic peptide studied for cognitive effects.
- The FDA staff position, stated in the pre-meeting review, is that none of these meet the clinical evidence threshold the agency typically requires for compounding eligibility.
The honest reading: this is a regulatory decision being driven by demand and politics as much as by evidence. The compounds are real, the preclinical research is suggestive, and the human data is thin. The vote changes the regulatory environment, not the underlying evidence base. People who use these peptides should not suddenly feel more confident about the science because a committee voted yes - and people who study them should not feel less confident about the research interest because the FDA staff said no.
The Australia angle
For the Australian community, the US vote matters in two ways. First, it signals where the global regulatory conversation is heading - several of these compounds are already widely used here, and a US pathway that legitimises compounding gives local advocacy and grey-market-harm-reduction conversations a reference point. Second, it does not change a single thing about Australian law. The TGA has its own framework, and 2026 has been the year of enforcement rather than liberalisation.
The other Australian-relevant note is quality. Our recent reporting on black-market peptide testing showed exactly what happens when demand outruns regulated supply: vials at wrong doses, over-strength products, and no quality assurance anywhere in the chain. The US committee’s harm-reduction argument is basically that same problem in reverse - they would rather have the product in a regulated system than watch people inject unverified vials. That argument has real force, and it is the strongest single reason to watch closely what the FDA does next.
If the FDA accepts the recommendation, expect a gradual normalisation: compounding pharmacies advertising these peptides, purity certificates becoming standard, and the online market shifting toward legal supply. If the FDA sits on it, expect the status quo to continue, with the grey market doing what grey markets do.
Either way, the compound pages on this site track the research behind each of these peptides, and the Grey Highway Telegram community is a good place to watch the fallout with other researchers.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.
Sources: ABC News, “FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What’s next?”, 24 July 2026 (syndicated at AOL: https://www.aol.com/articles/fda-advisers-narrowly-vote-add-224426000.html). Time, “An FDA Committee Just Voted in Favor of Peptides - Despite the Agency’s Opposition”, 23 July 2026. FDA Pharmacy Compounding Advisory Committee hearing transcript, 23-24 July 2026.